Immuno-oncology drugs, including immune checkpoint inhibitors targeting CTLA-4 and the PD-1/PD-L1 axis are rapidly changing the therapeutic possibilities for traditionally difficult-to-treat cancers including melanoma, renal and lung cancers, but responses are variable across and within cancer types. This evidence concerns the gene CD274 and melanoma.